Summary
600m people globally suffer from autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis. The symptoms can be severe, causing intense pain and suffering for patients. The cost of RA alone for Europe is €45.3 billion p.a.
A growing need: Unlike diabetes patients for example who can measure their own blood sugar levels, there is currently no method to measure disease activity quickly and accurately for autoimmune patients, non-invasively at home. Furthermore, most autoimmune diseases have unpredictable flares in disease activity despite stable medication, and the causes of such flares differ between patients and are largely unidentifiable.
Our deep-tech innovation is an Artificial Intelligence approach to the Monitoring of Autoimmune Diseases at Home with a Novel Biomarker Algorithm: Through 15 years of research in this field, the founder of Kaass Discovery, Dr Anita Kaass, has shown a key biomarker, Gonadotropin releasing hormone (GnRH), is common to several autoimmune diseases. It has been scientifically shown that GnRH levels increase with increasing disease activity.
Kaass Discovery is developing a highly novel, deep tech solution to allow autoimmune disease patients to self-manage their conditions and minimize or even eliminate the symptoms of autoimmune diseases. The solution, which we call ‘a-Doc’, uses a saliva sample to indicate disease activity and provide an accurate, instantaneous value. In line with this need, it is also low cost, accurate and simple to use ensuring it is suitable for home use. The data collected from the device will be sent to the Kaass Discovery Cloud for improving the predictive analytical models, and giving an individualised meaningful result to the user on their mobile device
The aims of the Women TechEU programme align perfectly with the needs of Kaass Discovery. The business coaching support provided will ensure we are prepared and able to successfully commercialise this exciting technology.
A growing need: Unlike diabetes patients for example who can measure their own blood sugar levels, there is currently no method to measure disease activity quickly and accurately for autoimmune patients, non-invasively at home. Furthermore, most autoimmune diseases have unpredictable flares in disease activity despite stable medication, and the causes of such flares differ between patients and are largely unidentifiable.
Our deep-tech innovation is an Artificial Intelligence approach to the Monitoring of Autoimmune Diseases at Home with a Novel Biomarker Algorithm: Through 15 years of research in this field, the founder of Kaass Discovery, Dr Anita Kaass, has shown a key biomarker, Gonadotropin releasing hormone (GnRH), is common to several autoimmune diseases. It has been scientifically shown that GnRH levels increase with increasing disease activity.
Kaass Discovery is developing a highly novel, deep tech solution to allow autoimmune disease patients to self-manage their conditions and minimize or even eliminate the symptoms of autoimmune diseases. The solution, which we call ‘a-Doc’, uses a saliva sample to indicate disease activity and provide an accurate, instantaneous value. In line with this need, it is also low cost, accurate and simple to use ensuring it is suitable for home use. The data collected from the device will be sent to the Kaass Discovery Cloud for improving the predictive analytical models, and giving an individualised meaningful result to the user on their mobile device
The aims of the Women TechEU programme align perfectly with the needs of Kaass Discovery. The business coaching support provided will ensure we are prepared and able to successfully commercialise this exciting technology.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101072251 |
| Start date: | 01-07-2022 |
| End date: | 30-06-2023 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
600m people globally suffer from autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis. The symptoms can be severe, causing intense pain and suffering for patients. The cost of RA alone for Europe is €45.3 billion p.a.A growing need: Unlike diabetes patients for example who can measure their own blood sugar levels, there is currently no method to measure disease activity quickly and accurately for autoimmune patients, non-invasively at home. Furthermore, most autoimmune diseases have unpredictable flares in disease activity despite stable medication, and the causes of such flares differ between patients and are largely unidentifiable.
Our deep-tech innovation is an Artificial Intelligence approach to the Monitoring of Autoimmune Diseases at Home with a Novel Biomarker Algorithm: Through 15 years of research in this field, the founder of Kaass Discovery, Dr Anita Kaass, has shown a key biomarker, Gonadotropin releasing hormone (GnRH), is common to several autoimmune diseases. It has been scientifically shown that GnRH levels increase with increasing disease activity.
Kaass Discovery is developing a highly novel, deep tech solution to allow autoimmune disease patients to self-manage their conditions and minimize or even eliminate the symptoms of autoimmune diseases. The solution, which we call ‘a-Doc’, uses a saliva sample to indicate disease activity and provide an accurate, instantaneous value. In line with this need, it is also low cost, accurate and simple to use ensuring it is suitable for home use. The data collected from the device will be sent to the Kaass Discovery Cloud for improving the predictive analytical models, and giving an individualised meaningful result to the user on their mobile device
The aims of the Women TechEU programme align perfectly with the needs of Kaass Discovery. The business coaching support provided will ensure we are prepared and able to successfully commercialise this exciting technology.
Status
SIGNEDCall topic
HORIZON-EIE-2021-SCALEUP-01-03Update Date
09-02-2023
Images
No images available.
Geographical location(s)
